Literature DB >> 15962999

Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis.

Andrew J Dowson1, David W Dodick, Volker Limmroth.   

Abstract

Medication overuse headache (MOH) is a common medical condition that is associated with considerable long-term morbidity and disability. Patients experiencing MOH have primary headache disorders (migraine, tension-type headache [TTH] or the combination of migraine and TTH) that change to a pattern of daily or near-daily headaches over a period of years or decades following the overuse of symptomatic headache medications. Overused drugs include analgesics, ergot alkaloids, serotonin 5-HT(1B/1D) receptor agonists ('triptans') and medications containing barbiturates, codeine, caffeine, tranquillisers and mixed analgesics. Affected patients usually have a long history of primary headache, overuse of medications and MOH before they consult a physician for care. Patients with MOH are usually managed in specialist centres by withdrawal of the overused drugs and treatment of withdrawal symptoms (on an inpatient or outpatient basis), headache prophylaxis and limited use of symptomatic acute medications. Most patients respond to this therapy, although the prognosis is not always good and >or=50% may lapse over an initial 5-year follow-up period. The best practical strategy at present is to prevent the overuse of drugs in the first place by patient education and formal management approaches conducted in primary care to treat the primary headache before it changes to MOH. The quality of the clinical evidence on MOH is suboptimal and further biological and clinical research is urgently required to help facilitate the management of these patients more effectively in the future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15962999     DOI: 10.2165/00023210-200519060-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  82 in total

1.  [Drug-induced headache and its treatment].

Authors:  I Barone-Kaganas
Journal:  Schweiz Med Wochenschr       Date:  1999-03-20

Review 2.  Chronic daily headache.

Authors:  S D Silberstein; R B Lipton
Journal:  Curr Opin Neurol       Date:  2000-06       Impact factor: 5.710

3.  Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache.

Authors:  R Hering-Hanit; N Gadoth; A Cohen; Z Horev
Journal:  J Child Neurol       Date:  2001-06       Impact factor: 1.987

4.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

Review 5.  Opioids.

Authors:  K M Foley
Journal:  Neurol Clin       Date:  1993-08       Impact factor: 3.806

6.  [Prophylaxis and treatment of drug-induced persistent headache. Therapy recommendation of the German Society for Migraine and Headache].

Authors:  G Haag; H Baar; K H Grotemeyer; V Pfaffenrath; M J Ribbat; H C Diener
Journal:  Schmerz       Date:  1999-02-18       Impact factor: 1.107

7.  [Primary chronic daily headache: a report on 52 cases].

Authors:  C da C Jevoux; P F Moreira Filho; J A de Souza
Journal:  Arq Neuropsiquiatr       Date:  1998-03       Impact factor: 1.420

8.  Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study.

Authors:  J-A Zwart; G Dyb; K Hagen; S Svebak; J Holmen
Journal:  Neurology       Date:  2003-07-22       Impact factor: 9.910

9.  Chronic use of symptomatic headache medications.

Authors:  Michael Von Korff; Bradley S Galer; Paul Stang
Journal:  Pain       Date:  1995-08       Impact factor: 6.961

Review 10.  [Headache caused by analgesic and/or ergotamine abuse].

Authors:  A Panconesi; P L Del Bianco; C Curradi; G Franchi; B Anselmi; R Andreini
Journal:  Clin Ter       Date:  1991-05-15
View more
  11 in total

1.  Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers.

Authors:  Milena De Felice; Michael H Ossipov; Ruizhong Wang; Gregory Dussor; Josephine Lai; Ian D Meng; Juliana Chichorro; John S Andrews; Suman Rakhit; Shawn Maddaford; David Dodick; Frank Porreca
Journal:  Brain       Date:  2010-07-13       Impact factor: 13.501

2.  Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache.

Authors:  Sarah Cargnin; Michele Viana; Grazia Sances; Marika Bianchi; Natascia Ghiotto; Cristina Tassorelli; Giuseppe Nappi; Pier Luigi Canonico; Armando A Genazzani; Salvatore Terrazzino
Journal:  Eur J Clin Pharmacol       Date:  2014-08-07       Impact factor: 2.953

3.  Triptan-induced latent sensitization: a possible basis for medication overuse headache.

Authors:  Milena De Felice; Michael H Ossipov; Ruizhong Wang; Josephine Lai; Juliana Chichorro; Ian Meng; David W Dodick; Todd W Vanderah; Gregory Dussor; Frank Porreca
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

4.  Sustained morphine-induced sensitization and loss of diffuse noxious inhibitory controls in dura-sensitive medullary dorsal horn neurons.

Authors:  Akiko Okada-Ogawa; Frank Porreca; Ian D Meng
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

5.  Drug-dependence behaviour and outcome of medication-overuse headache after treatment.

Authors:  Ilenia Corbelli; Stefano Caproni; Paolo Eusebi; Paola Sarchielli
Journal:  J Headache Pain       Date:  2012-10-18       Impact factor: 7.277

6.  Tension-type Headache in the Elderly.

Authors:  Robert G Kaniecki
Journal:  Curr Treat Options Neurol       Date:  2007-01       Impact factor: 3.598

Review 7.  Over-the-counter triptans for migraine : what are the implications?

Authors:  Peer Tfelt-Hansen; Timothy J Steiner
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 8.  [Therapy of primary chronic headache: chronic migraine, chronic tension type headache and other forms of daily chronic headache].

Authors:  A Straube; A May; P Kropp; Z Katsarava; G Haag; C Lampl; P S Sándor; H-C Diener; S Evers
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

Review 9.  Meeting patient expectations in migraine treatment: what are the key endpoints?

Authors:  Fabio Antonaci; Grazia Sances; Elena Guaschino; Ilaria De Cillis; Giorgio Bono; Giuseppe Nappi
Journal:  J Headache Pain       Date:  2008-07-08       Impact factor: 7.277

10.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.